SHANGHAI JUNSHI BIO YC1 (8SJ) - Total Assets
Based on the latest financial reports, SHANGHAI JUNSHI BIO YC1 (8SJ) holds total assets worth €11.69 Billion EUR (≈ $13.67 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SHANGHAI JUNSHI BIO YC1 shareholders equity for net asset value and shareholders' equity analysis.
SHANGHAI JUNSHI BIO YC1 - Total Assets Trend (2021–2024)
This chart illustrates how SHANGHAI JUNSHI BIO YC1's total assets have evolved over time, based on quarterly financial data.
SHANGHAI JUNSHI BIO YC1 - Asset Composition Analysis
Current Asset Composition (December 2024)
SHANGHAI JUNSHI BIO YC1's total assets of €11.69 Billion consist of 39.7% current assets and 60.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 23.0% |
| Accounts Receivable | €509.82 Million | 4.7% |
| Inventory | €584.47 Million | 5.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €120.50 Million | 1.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how SHANGHAI JUNSHI BIO YC1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is SHANGHAI JUNSHI BIO YC1 worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SHANGHAI JUNSHI BIO YC1's current assets represent 39.7% of total assets in 2024, a decrease from 52.8% in 2021.
- Cash Position: Cash and equivalents constituted 23.0% of total assets in 2024, down from 31.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 5.4% of total assets.
SHANGHAI JUNSHI BIO YC1 Competitors by Total Assets
Key competitors of SHANGHAI JUNSHI BIO YC1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
SHANGHAI JUNSHI BIO YC1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.59 | 2.07 | - |
| Quick Ratio | 1.41 | 1.83 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €1.78 Billion | €2.49 Billion | - |
SHANGHAI JUNSHI BIO YC1 - Advanced Valuation Insights
This section examines the relationship between SHANGHAI JUNSHI BIO YC1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.83 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -4.9% |
| Total Assets | €10.80 Billion |
| Market Capitalization | $870.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values SHANGHAI JUNSHI BIO YC1's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: SHANGHAI JUNSHI BIO YC1's assets decreased by 4.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for SHANGHAI JUNSHI BIO YC1 (2021–2024)
The table below shows the annual total assets of SHANGHAI JUNSHI BIO YC1 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €10.80 Billion ≈ $12.63 Billion |
-4.95% |
| 2023-12-31 | €11.36 Billion ≈ $13.28 Billion |
-9.65% |
| 2022-12-31 | €12.58 Billion ≈ $14.70 Billion |
+13.81% |
| 2021-12-31 | €11.05 Billion ≈ $12.92 Billion |
-- |
About SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more